The disclosure relates to salts of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium, specifically the (2E)-3-carboxyacrylate, 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate and dihydrogenphosphate salt. The disclosure also relates to the process for preparing said salts and the use of these salts in the treatment of cardiovascular diseases, such as ischemic heart diseases like myocardial infarction.